Independent Investors Inc. maintained its stake in shares of Allergan PLC (NYSE:AGN) during the second quarter, Holdings Channel reports. The fund owned 5,500 shares of the company’s stock at the end of the second quarter. Independent Investors Inc.’s holdings in Allergan PLC were worth $1,270,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Barnett & Company Inc. purchased a new stake in shares of Allergan PLC during the first quarter worth approximately $111,000. Livingston Group Asset Management CO operating as Southport Capital Management purchased a new stake in shares of Allergan PLC during the second quarter worth approximately $125,000. Trust Co. of Vermont raised its stake in shares of Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares during the last quarter. Integrated Investment Consultants LLC raised its stake in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock worth $137,000 after buying an additional 154 shares during the last quarter. Finally, Trust Department MB Financial Bank N A raised its stake in shares of Allergan PLC by 77.4% in the second quarter. Trust Department MB Financial Bank N A now owns 653 shares of the company’s stock worth $198,000 after buying an additional 285 shares during the last quarter. Hedge funds and other institutional investors own 85.20% of the company’s stock.
Allergan PLC (NYSE:AGN) traded down 1.56% on Monday, hitting $223.99. The company had a trading volume of 3,669,850 shares. The stock has a 50 day moving average of $238.01 and a 200-day moving average of $238.04. The stock has a market capitalization of $88.69 billion, a PE ratio of 21.33 and a beta of 0.81. Allergan PLC has a one year low of $195.50 and a one year high of $322.68.
Allergan PLC (NYSE:AGN) last announced its earnings results on Monday, August 8th. The company reported $3.35 EPS for the quarter, beating the consensus estimate of $3.34 by $0.01. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the prior year, the company earned $4.41 EPS. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. Equities analysts anticipate that Allergan PLC will post $14.00 EPS for the current year.
A number of analysts recently commented on the company. Deutsche Bank AG set a $278.00 price objective on Allergan PLC and gave the stock a “buy” rating in a research report on Saturday. Mizuho reiterated a “hold” rating and issued a $232.00 price objective on shares of Allergan PLC in a research report on Monday, July 11th. RBC Capital Markets reiterated an “outperform” rating and issued a $300.00 price objective (down from $307.00) on shares of Allergan PLC in a research report on Wednesday, August 10th. Piper Jaffray Cos. set a $227.00 price objective on Allergan PLC and gave the stock a “hold” rating in a research report on Tuesday, August 9th. Finally, Morgan Stanley restated an “overweight” rating on shares of Allergan PLC in a report on Wednesday, June 29th. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $302.23.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.